Regeneron Pharmaceuticals Inc.

REGN | NASDAQ

Price Alert Chart Builder DCF Calculator

$790.93

+$6.26 (+0.80%)

Sep 21, 2026, 11:05 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Dividends Profile

+0.80%

(1D)

Rating

Updated: Aug 13, 2026

50.5

Fundamentals Strong

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $81.48B

1D Range

779.96 792.68

52W Range

541 859.34

Valuation (TTM)

PE 19.41

PB 2,549,771.27

EV/EBITDA 15.99

Valuation (NTM)

Forward PE 12.25

Forward PEG 1.52

Price Target $827.71

Cash Flow

FCF Yield 4.4%

SBC Adj. FCF Yield 3.1%

SBC Impact -28.0%

Margins

Gross Margin 84.9%

Operating Margin 24.7%

FCF Margin 22.7%

Growth (CAGR)

Revenue 3Y | 5Y 7.0% | 4.6%

Dil EPS 3Y | 5Y 2.2% | -6.2%

FCF 3Y | 5Y -5.3% | 15.8%

Returns

ROA 10.4%

ROE 13.8%

ROIC 9.2%

Financial Health

Net Cash

$6.01K

Current Ratio 3.34

Interest Coverage 71.66

Dividends

Div Yield 0.47%

Payout Ratio 9.2%

FCF Payout Ratio 10.8%

All Key Statistics

Loading financial charts...

Profile

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of ill...

Sector Healthcare

Industry Biotechnology

Employees 15,410

IPO Date Apr 1, 1991

Website www.regeneron.com

Fiscal Year January - December

Full Company Profile

Latest News

6 days ago · marketbeat.com

Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum

Regeneron Pharmaceuticals NASDAQ: REGN outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference.

6 days ago · seekingalpha.com

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

7 days ago · prnewswire.com

REGN DEADLINE ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. Investors to Today's September 14, 2026 Lead Plaintiff Deadline in Securities Class Action

SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.

7 days ago · businesswire.com

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

NEW YORK--(BUSINESS WIRE)---- $REGN #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and.

7 days ago · globenewswire.com

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

8 days ago · globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Regeneron (REGN) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/14/2026

10 days ago · newsfilecorp.com

INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit Before September 14, 2026 Deadline

San Francisco, California--(Newsfile Corp. - September 11, 2026) - Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.

10 days ago · globenewswire.com

REGN SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options

10 days ago · globenewswire.com

MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - REGN

SAN DIEGO, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the “Class Period”), have until this Monday, September 14, 2026 to seek appointment as lead plaintiff of the Regeneron class action lawsuit.